Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PLX 200

Next Previous
Drug Profile

PLX 200

Alternative Names: PLX-200

Latest Information Update: 03 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Polaryx Therapeutics
  • Class Anti-inflammatories; Neuroprotectants; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Peroxisome proliferator-activated receptor alpha agonists; Retinoid X receptor agonists; Tripeptidyl-peptidase 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Globoid cell leukodystrophy; Neuronal ceroid lipofuscinosis; GM2 gangliosidoses
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neuronal ceroid lipofuscinosis
  • Phase I Globoid cell leukodystrophy; Tay-Sachs disease

Most Recent Events

  • 03 Jan 2024 Phase-I clinical trials in Globoid cell leukodystrophy (PO) (Polaryx Therapeutics pipeline, January 2024) (Polaryx Therapeutics pipeline, January 2023)
  • 03 Jan 2024 Phase-I clinical trials in Tay-Sachs disease (PO) (Polaryx Therapeutics pipeline, January 2024) (Polaryx Therapeutics pipeline, January 2023)
  • 07 Sep 2021 PLX 200 receives Orphan Drug status for Globoid cell leukodystrophy in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top